STEMFORSTROKE
Secretome analysis of intrathecally applied bone marrow stromal cells in experimental stroke
| Coordinatore | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 168˙794 € |
| EC contributo | 168˙794 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-IEF |
| Funding Scheme | MC-IEF |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-03-01 - 2016-02-29 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | coordinator | 168˙794.40 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Bone marrow stromal cells (BMSCs) have been shown to be neuroprotective after experimental ischemic stroke when given systemically. By this route of administration, however, over 99% of cells are trapped in lung, spleen and kidneys. This off-target distribution of BMSCs may result in serious ectopic side-effects thereby making their use in humans questionable.
The applicant’s previous work has demonstrated that transplantation of BMSCs to the cerebrospinal fluid compartment (CSFC) reduces post-ischemic brain damage. The cells circulate in the CSFC, attach to ventricular walls and potentially undergo cell-host interactions. Nevertheless, their presence seems sufficient to provide suitable trophic support and promote tissue repair, suggesting a secretory mechanism of action (secretome). Whether the beneficial effect is solely due to the BMSCs secretome in the CSFC or to cross-talk mechanisms between BMSCs and the brain is not clarified. A better understanding of these potential modes of action offers a promising opportunity for future development of 'cell-free' based therapy.
In this project, we seek to go ahead by studying the CSFC secretome and the observed cell-host interactions of BMSCs after experimental stroke by using state-of-art techniques such as Laser Capture Microdissection and Mass Spectroscopy. The ultimate goal of the project is to determine whether a 'cell-free' CSFC secretome, which is devoid of any cell-specific side-effects, recapitulates the effects of transplanted BMSCs.
Taken together, this project will analyze the in vivo BMSCs-secretome after cerebral ischemia and will translationally demonstrate the pre-clinical proof-of-concept of a “cell-free” BMSCs therapy for stroke. Due to the high socioeconomic burden of stroke for Europe, novel and effective treatments are urgently needed.'